Food and Drug Administration
Center for Drug Evaluation and Research

Summary Minutes of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee Joint Meeting
September 14, 2017

Location: Tommy Douglas Conference Center, 10000 New Hampshire Ave, Silver Spring, Maryland.

Topic: On September 14, 2017, the committees were asked to discuss supplemental new drug application (sNDA) 021306, for Butrans (buprenorphine) transdermal system, submitted by Purdue Pharma LP, evaluating Butrans in pediatric patients ages 7 through 16 years. The committees discussed the findings of the clinical study of Butrans conducted in pediatric patients, and whether they supported additional labeling.

These summary minutes for the September 14, 2017, joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee of the Food and Drug Administration were approved on September 29, 2017.

I certify that I attended the September 14, 2017, joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee of the Food and Drug Administration and that these minutes accurately reflect what transpired.

/s/ Stephanie L. Begansky, PharmD
Designated Federal Officer, AADPAC

/s/ Brian T. Bateman, MD, MSc
Acting Chairperson, AADPAC
Summary Minutes of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee Joint Meeting  
September 14, 2017

The following is the final report of the joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee, held on September 14, 2017. A verbatim transcript will be available in approximately six weeks, sent to the Division of Analgesia, Anesthesia and Addiction Products and the Office of Safety and Epidemiology and posted on the FDA website at:  
https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSafetyandRiskManagementAdvisoryCommittee/ucm536632.htm and  
https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndAnalgesicDrugProductsAdvisoryCommittee/ucm536646.htm

All external requests for the meeting transcript should be submitted to the CDER Freedom of Information Office.

The Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee of the Food and Drug Administration, Center for Drug Evaluation and Research, met jointly on September 14, 2017, at the Tommy Douglas Conference Center, 10000 New Hampshire Ave, Silver Spring, Maryland. Prior to the meeting, the members and temporary voting members were provided the briefing materials from the FDA and Purdue Pharma LP. The meeting was called to order by Brian Bateman, MD, MSc (Acting Chairperson). The conflict of interest statement was read into the record by Stephanie Begansky, PharmD (Designated Federal Officer). There were approximately 60 people in attendance. There was one Open Public Hearing (OPH) speaker presentation.

Issue: The committees were asked to discuss supplemental new drug application (sNDA) 021306, for Butrans (buprenorphine) transdermal system, submitted by Purdue Pharma LP, evaluating Butrans in pediatric patients ages 7 through 16 years. The committees discussed the findings of the clinical study of Butrans conducted in pediatric patients, and whether they supported additional labeling.

Attendance:

Anesthetic and Analgesic Drug Products Advisory Committee Members Present (Voting):  
Brian T. Bateman, MD, MSc (Acting Chairperson); Jennifer G. Higgins, PhD (Consumer Representative); Ronald S. Litman, DO; Mary Ellen McMann, MD, MPH; Abigail B. Shoben, PhD; Kevin L. Zacharoff, MD, FACIP, FACPE, FAAP

Anesthetic and Analgesic Drug Products Advisory Committee Members Not Present (Voting):  
Raeford E. Brown, Jr., MD, FAAP; David S. Craig, PharmD; Jeffrey L. Galinkin, MD, FAAP; Anita Gupta, DO, PharmD; Lonnie Zeltzer, MD

Anesthetic and Analgesic Drug Products Advisory Committee Member Not Present (Non-Voting):  
William Joseph Herring, MD, PhD (Industry Representative)
September 14, 2017
Joint Meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee

Drug Safety and Risk Management Advisory Committee Members Present (Voting): Laurel A. Habel, MPH, PhD; Suzanne B. Robotti (Consumer Representative); Anne-Michelle Ruha, MD, FACMT; Christopher H. Schmid, PhD; Terri L. Warholak, PhD, RPh, FAPhA

Drug Safety and Risk Management Advisory Committee Members Not Present (Voting): Almut Winterstein, RPh, PhD, FISPE; Kelly Besco, PharmD, FISMP, CPPS; Denise M. Boudreau, PhD, RPh; Niteesh K. Choudhry, MD, PhD; Steven B. Meisel, PharmD; Soko Setoguchi, MD, DrPh

Drug Safety and Risk Management Advisory Committee Member Present (Non-Voting): Linda Scarazzini, MD, RPh (Industry Representative)

Temporary Members (Voting): Robert Dracker, MD, MHA, MBA; Charles W. Emala, Sr., MS, MD; Randall Flick, MD, MPH; William L. Greene, PharmD; Peter L. Havens, MD, MS; Stephen W. Patrick, MD, MPH, MS, FAAP; Natalie C. Portis (Patient Representative); Kelly Wade, MD, PhD, MSCE

FDA Participants (Non-Voting): Sharon Hertz, MD; Judy Staffa, PhD, RPh

Designated Federal Officer (Non-Voting): Stephanie Begansky, PharmD

Open Public Hearing Speaker: Megan Polanin, PhD (National Center for Health Research Cancer Prevention and Treatment Fund)

The agenda was as follows:

Call to Order and Introduction of Committee: Brian Bateman, MD, MSc
Acting Chairperson, AADPAC

Conflict of Interest Statement: Stephanie Begansky, PharmD
Designated Federal Officer, AADPAC

FDA Opening Remarks: Sharon Hertz, MD
Director, Division of Anesthesia, Analgesia, and Addiction Products (DAAAP)
Office of Drug Evaluation II (ODE-II)
Office of New Drugs (OND), CDER, FDA

SPONSOR PRESENTATIONS: Purdue Pharma, L.P.

Introduction and Pediatric Study Context: Craig Landau, MD
President & CEO

Regulatory History: Richard Fanelli, PhD
Head of Regulatory Affairs

Utilization of Opioids in Pediatric Patients
Questions to the Committee:

1. **DISCUSSION:** Please discuss any concerns you have regarding the data from the evaluation of Butrans in pediatric patients.

   **Committee Discussion:** Overall, the committees were concerned that the study of Butrans in pediatric patients did not have an adequate sample size and the patient population that was...
studied was not representative of all those who would receive treatment in the clinical setting (i.e. oncology and palliative care patients, patients on concomitant QT prolonging agents). There was also discussion surrounding the need for endpoints such as hyper-somnolence and QT prolongation to be better studied. Furthermore, the committee members stated that more data are needed to characterize the importance of body weight, potential safety signals, consequences of using additional QT prolonging products (i.e. ondansetron) and the efficacy of the doses used in the study. Please see the transcript for details of the committee discussion.

2. DISCUSSION: Please discuss whether information from Study 3031 should be added to Section 8.4 Pediatric Use, in the Butrans label.

Committee Discussion: The committee members expressed mixed opinions on whether or not Study 3031 should be included in Section 8.4 Pediatric Use in the Butrans label. There was concern from some committee members that inappropriate conclusions may be made about the study if it were added to the label, including assumptions that this is a robust study with adequate data for clinical decision-making and therefore this may unintentionally deceive prescribers that do not thoroughly read the entire label. A few committee members expressed that including the study information in the label could be useful and valuable to prescribers, although the general consensus of the committee was that if the study is mentioned there should be clearly written statements about weight-based dosing, potential restrictions of use, limitations of the study, and contraindications along with a statement regarding the study’s lack of robust safety data. Please see the transcript for details of the committee discussion.

3. DISCUSSION: Please discuss whether any additional labeling changes are supported by the data from Study 3031.

Committee Discussion: Based on the committees’ discussion of question #2, the committees did not have anything further to add. Please see the transcript for details of the committee discussion.

The meeting was adjourned at approximately 11:58 a.m.